Voyager Therapeutics price target lowered to $8 from $9 at Wedbush

Wedbush lowered the firm’s price target on Voyager Therapeutics (VYGR) to $8 from $9 and keeps an Outperform rating on the shares. The firm notes the quarterly update reported runway extension from mid-2027 to 2028 with end of Q2 total cash of $262M through restructuring and improving execution efficiency. There appears to be no impact on the pipeline, which in fact was recently further expanded when Voyager announced a fourth wholly owned GTx program that leverages a TRACER capsid to IV-deliver a bifunctional payload to decrease the expression of APOE in APOE4 carriers while increasing the expression of the protective variant APOE2. All other programs remain on track, Wedbush adds.